ApiquestUSA Secures Landmark U.S. Patent, Propelling Apivirine to the Forefront of Natural Antiviral Innovation"

U.S. Patent No. 12,201,662 B2 Validates ApiquestUSA's Science-Driven Approach and Strengthens the Intellectual Property Foundation of Its Award-Winning Apivirine Platform

STERLING, VA, April 16, 2026 /24-7PressRelease/ -- ApiquestUSA Inc. proudly announces the recent acceptance and issuance of U.S. Patent No. 12,201,662 B2, "Compositions and Methods for Treating COVID-19 Infections with an Extract of Dichrostachys glomerata." This milestone reinforces the company's scientific foundation and strengthens the intellectual property position behind Apivirine, ApiquestUSA's natural antiviral innovation platform.

The patent marks an important step forward in ApiquestUSA's mission to expand Apivirine into a complete product range built around the promise of natural antiviral science. From dietary and wellness applications to future food and beverage concepts, the Apivirine platform is designed to support innovation that is both commercially scalable and aligned with modern consumer demand for all-natural, plant-based solutions.

Apivirine's recognition with the Geneva Invention Award since 2009 reflects the strength of its mission, its botanical heritage, and its potential to contribute to new categories of health-focused products. These accomplishments highlight ApiquestUSA's commitment to excellence, responsible development, and the advancement of natural solutions that can serve a diverse global market.

ApiquestUSA is committed to developing Apivirine in accordance with applicable FDA guidance and regulatory expectations, including a science-driven approach to safety, quality, and antiviral development. By following appropriate regulatory pathways and maintaining high standards of product integrity, the company aims to contribute meaningfully to a healthier world through responsible innovation.

"As we build the Apivirine platform, our goal is to combine patent-backed innovation, award-winning vision, and regulatory discipline," said Mbaye Diagne, CEO of ApiquestUSA Inc. "This milestone supports our long-term commitment to creating natural antiviral solutions that can make a positive contribution to wellness, public health, and the future of food and drink."

ApiquestUSA believes this achievement positions Apivirine as a forward-looking platform with the potential to inspire a broader category of natural, science-backed products that serve consumers, support innovation, and reflect the company's dedication to a healthier world.

"ApiquestUSA Inc. is a Sterling, Virginia-based life sciences and natural health innovation company dedicated to the research, development, and commercialization of plant-based antiviral solutions. The company's flagship platform, Apivirine, is derived from an extract of Dichrostachys glomerata and has been recognized with the Geneva Invention Award since 2009. ApiquestUSA is committed to advancing natural antiviral science through responsible innovation, rigorous regulatory compliance, and a science-driven approach to product development. The company's mission is to deliver safe, effective, and scalable natural health solutions that serve consumers and contribute to a healthier world."

Website: https://www.apiquestusahealth.com

Read the full story here: https://www.24-7pressrelease.com/press-release/533895/apiquestusa-secures-landmark-us-patent-propelling-apivirine-to-the-forefront-of-natural-antiviral-innovation

Press Release Service and Press Release Distribution by 24-7 Press Release Newswire